NCT00730379 - A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Neoplasms

Interventions

DRUG

Comparator: ridaforolimus + dalotuzumab

Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).